| Larry A Zieske, MD | |
|
2211 Park Ave, Minneapolis, MN 55404-3711 | |
| (612) 871-1144 | |
| (612) 871-2012 |
| Full Name | Larry A Zieske |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | 2211 Park Ave, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841292646 | NPI | - | NPPES |
| 76D32ZI | Other | MN | BLUE SHIELD |
| 1000010 | Other | MN | MEDICA PRIMARY |
| 1000133 | Other | MN | MEDICA CHOICE |
| 32466700 | Other | WI | MEDICAID - WISCONSIN |
| 639817100 | Medicaid | MN | |
| 1016754 | Other | MN | PREFERREDONE |
| 768882 | Other | MN | AMERICA'S PPO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 37062 (Minnesota) | Primary |
| Entity Name | Ear Nose & Throat Specialty Care Of Minnesota Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336175744 PECOS PAC ID: 3274524020 Enrollment ID: O20051116000590 |
News Archive
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
The first study to monitor physical activity in breast cancer patients for five years suggests that patients with greater depressive symptoms and a lower emotional quality of life are less likely to exercise as part of their recovery than are patients reporting less distress.
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
A majority of Americans would not take an H1N1 flu vaccine or drug additive authorized for emergency use by the Food and Drug Administration, according to a University of Pittsburgh Graduate School of Public Health and University of Georgia study. The study, available online today in Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, found that fewer than 10 percent of those surveyed said they would be willing to take such a vaccine or drug and nearly 30 percent remained undecided.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Larry A Zieske, MD 2211 Park Ave, Minneapolis, MN 55404-3711 Ph: (612) 871-1144 | Larry A Zieske, MD 2211 Park Ave, Minneapolis, MN 55404-3711 Ph: (612) 871-1144 |
News Archive
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
The first study to monitor physical activity in breast cancer patients for five years suggests that patients with greater depressive symptoms and a lower emotional quality of life are less likely to exercise as part of their recovery than are patients reporting less distress.
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
A majority of Americans would not take an H1N1 flu vaccine or drug additive authorized for emergency use by the Food and Drug Administration, according to a University of Pittsburgh Graduate School of Public Health and University of Georgia study. The study, available online today in Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, found that fewer than 10 percent of those surveyed said they would be willing to take such a vaccine or drug and nearly 30 percent remained undecided.
› Verified 9 days ago
Jeffrey C. Manlove, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2211 Park Ave, Minneapolis, MN 55404 Phone: 612-871-1144 Fax: 612-871-2012 | |
Richard M. Levinson, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2211 Park Ave, Minneapolis, MN 55404 Phone: 612-871-1144 Fax: 612-871-2012 | |
Robert H Maisel, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 701 Park Ave, P7, Minneapolis, MN 55415 Phone: 612-873-2424 | |
Sivakumar Chinnadurai, MD, MPH Otolaryngology Medicare: Medicare Enrolled Practice Location: 2530 Chicago Ave Ste 450, Minneapolis, MN 55404 Phone: 615-813-6000 | |
Samir Suresh Khariwala, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 516 Delaware St Se, Clinic 8a, Minneapolis, MN 55455 Phone: 612-625-7400 | |
Tina Chung-ting Huang, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 420 Delaware St Se, University Of Minnesota Physicians, Minneapolis, MN 55455 Phone: 612-626-5900 | |
Carrie E Flanagan, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 420 Delaware St Se, Mmc 293, Minneapolis, MN 55455 Phone: 612-625-7634 |